HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

[1]  J. Wagner,et al.  Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. , 2007, Blood.

[2]  B. Sandmaier,et al.  Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  R. Fanin,et al.  A comparison of allografting with autografting for newly diagnosed myeloma. , 2007, The New England journal of medicine.

[4]  J. Rowe,et al.  Alternative donor transplantation in acute myeloid leukemia: which source and when? , 2007, Current opinion in hematology.

[5]  M. Boeckh,et al.  Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  K. Sullivan,et al.  Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Allen R. Chen,et al.  6: Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent GVHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA matched related and unrelated bone marrow transplantation (BMT) , 2007 .

[8]  B. Yeap,et al.  Double unrelated reduced-intensity umbilical cord blood transplantation in adults. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  C. R. Allen,et al.  Post-Transplantation High-Dose Cyclophosphamide (Cy) Is Effective Single Agent GVHD Prophylaxis That Permits Prompt Immune Reconstitution after Myeloablative HLA Matched Related and Unrelated Bone Marrow Transplantation (BMT). , 2006 .

[10]  T. Spitzer,et al.  Current status of haploidentical stem cell transplantation , 2006, British journal of haematology.

[11]  Yu-Hong Chen,et al.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. , 2006, Blood.

[12]  P. Wernet,et al.  Unrelated cord blood transplants in adults with hematologic malignancies. , 2006, Haematologica.

[13]  M. Maris,et al.  Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. , 2005, Blood.

[14]  H. Einsele,et al.  Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. , 2005, Blood.

[15]  C. Mecucci,et al.  Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Todd E DeFor,et al.  Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. , 2005, Blood.

[17]  J. Wagner,et al.  Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. , 2004, The New England journal of medicine.

[18]  T. Klingebiel,et al.  Long-term outcome after haploidentical stem cell transplantation in children. , 2004, Blood cells, molecules & diseases.

[19]  S. Lonial,et al.  Facilitating T-cell immune reconstitution after haploidentical transplantation in adults. , 2004, Blood cells, molecules & diseases.

[20]  M. Kami,et al.  Successful Engraftment After Reduced-Intensity Umbilical Cord Blood Transplantation for Adult Patients with Advanced Hematological Diseases , 2004, Clinical Cancer Research.

[21]  S. Singhal,et al.  Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients , 2004, Bone Marrow Transplantation.

[22]  F. Appelbaum,et al.  Thomas' hematopoietic cell transplantation , 2003 .

[23]  J. Wagner,et al.  Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. , 2003, Blood.

[24]  K. Matsuo,et al.  Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). , 2003, Blood.

[25]  M. Maris,et al.  Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. , 2003, Blood.

[26]  M. Maris,et al.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.

[27]  James Hope,et al.  Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. , 2003, Transplantation.

[28]  R. Storb,et al.  Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio , 2003, Blood.

[29]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[30]  M. Leffell,et al.  Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[31]  Lawrence Corey,et al.  Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  M. Maris,et al.  Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. , 2002, Blood.

[33]  R. Iannone,et al.  Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  R. Iannone,et al.  Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. , 2001, Blood.

[35]  C. Mecucci,et al.  Interphase FISH for Y chromosome, VNTR polymorphisms, and RT-PCR for BCR-ABL in the monitoring of HLA-matched and mismatched transplants. , 2000, Cancer genetics and cytogenetics.

[36]  D. Leonard,et al.  Bone marrow engraftment analysis after allogeneic bone marrow transplantation. , 2000, Clinics in laboratory medicine.

[37]  J. Gribben,et al.  Transplantation of anergic histoincompatible bone marrow allografts. , 1999, The New England journal of medicine.

[38]  S. Saidman,et al.  Mixed lymphohaemopoietic chimerism and graft-ver suslymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation , 1999, The Lancet.

[39]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[40]  I. Weissman,et al.  In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[42]  J P Klein,et al.  Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Miller,et al.  The use of amplified variable number of tandem repeats (VNTR) in the detection of chimerism following bone marrow transplantation. A comparison with restriction fragment length polymorphism (RFLP) by Southern blotting. , 1997, American journal of clinical pathology.

[44]  M. Umesue,et al.  [Cyclophosphamide-induced immunological tolerance: an overview]. , 1996, Nihon Geka Gakkai zasshi.

[45]  Y. Colson,et al.  A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. , 1995, Journal of immunology.

[46]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[47]  Richard J. Jones,et al.  Assessment of aldehyde dehydrogenase in viable cells. , 1995, Blood.

[48]  S. Lehnert,et al.  Amplification of the graft-versus-host reaction by cyclophosphamide: dependence on timing of drug administration. , 1994, Bone marrow transplantation.

[49]  K. Kinzler,et al.  Clues to the pathogenesis of familial colorectal cancer. , 1993, Science.

[50]  K. Yanaga,et al.  Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A. , 1992, Journal of immunology.

[51]  K. Sullivan,et al.  Chronic graft-versus-host disease and other late complications of bone marrow transplantation. , 1991, Seminars in hematology.

[52]  R. Storb,et al.  Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. , 1990, Human immunology.

[53]  K. Sullivan,et al.  Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. , 1989, The New England journal of medicine.

[54]  K. Tanaka,et al.  DRUG‐INDUCED TOLERANCE TO ALLOGRAFTS IN MICE: Xii. The Relationships Between Tolerance, Chimerism, and Graft‐Versus‐Host Disease , 1987, Transplantation.

[55]  B. Dupont,et al.  Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. , 1987, Transplantation.

[56]  B. Dupont,et al.  Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. , 1986, Blood.

[57]  K. Nomoto,et al.  Drug-induced tolerance to allografts in mice. VII. Optimal protocol and mechanism of cyclophosphamide-induced tolerance in an H-2 haplotype-identical strain combination. , 1986, Transplantation proceedings.

[58]  K. Nomoto,et al.  Drug-induced tolerance to allografts in mice. I. Difference between tumor and skin grafts. , 1984, Transplantation.

[59]  A. Fefer,et al.  CHEMOTHERAPY OF ESTABLISHED GRAFT‐VERSUS‐HOST DISEASE IN MICE , 1972, Transplantation.

[60]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[61]  A. Owens,et al.  THE EFFECT OF CYTOTOXIC DRUGS ON GRAFT‐VERSUS-HOST DISEASE IN MICE , 1971, Transplantation.

[62]  R. Storb,et al.  TREATMENT OF CANINE GRAFT-VERSUS-HOST DISEASE WITH METHOTREXATE AND CYCLOPHOSPHAMIDE FOLLOWING BONE MARROW TRANSPLANTATION FROM HISTOINCOMPATIBLE DONORS , 1970, Transplantation.

[63]  Owens Ah,et al.  A COMPARISON OF THE EFFECTS OF SELECTED CYTOTOXIC AGENTS ON ALLOGENEIC SKIN GRAFT SURVIVAL IN RATS. , 1965 .

[64]  A. Owens,et al.  A COMPARISON OF THE EFFECTS OF SELECTED CYTOTOXIC AGENTS ON ALLOGENEIC SKIN GRAFT SURVIVAL IN RATS. , 1965, Bulletin of the Johns Hopkins Hospital.

[65]  I. N. Brown,et al.  Prolongation of Homograft Survival in Mice with Single Doses of Cyclophosphamide , 1963, Nature.

[66]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .